Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Investor Presentation (April 2024)
15 slides from Mimedx's investor presentation, Apr 30, 2024
Slide 1: Investor Presentation May 2024
Exhibit 99.3 Investor Presentation May 2024 helping humans heal.
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth
Slide 3: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to ris
Slide 4: MIMEDX: Focused on Global Leadership in Healing Solutions
MIMEDX: Focused on Global Leadership in Healing Solutions Helping To be the leading global provider of Our Why Our healing solutions through relentless Humans Statement Vision innovation to restore quality of life. Heal Unparalleled Expertise Relentless Innovation Increasing Patient Access 15 >15 Ye
Slide 5: The Unmet Need for Healing Solutions Is Large and Growing
The Unmet Need for Healing Solutions Is Large and Growing million people are estimated to suffer from chronic, non-healing 7 1 wounds in the U.S. • Aging population • Obesity Favorable • Smoking history • Heart & vascular disease Demographic Trends • Diabetes • Millions of surgical procedures annual
Slide 6: Patient Journeys in Wound & Surgical
Patient Journeys in Wound & Surgical Meeting patients in settings where they receive care to drive continued adoption of MIMEDX’s products Wound Types Sites-of-Service Complex/Dehisced Hospital Inpatient Wounds Chronic Wounds Wound Care Centers Surgical Acute Wounds Private Office 6 S ever i t y
Slide 7: Expanding Breadth of Skin Substitutes
Expanding Breadth of Skin Substitutes Leading Human-Derived Portfolio Best-in-Class Wound Product Portfolio Innovative Offering for Surgical Market Emerging Xenograft Portfolio Announced exclusive manufacturing and supply agreement with Regenity Biosciences, a leading global developer and manufactur
Slide 8: Sizable, Expanding Opportunities in Wound & Surgical Markets
Sizable, Expanding Opportunities in Wound & Surgical Markets CAGRs* Total Addressable Markets +5% $4.9B +7% $0.7B $3.9B $0.5B +3% $2.5B $2.1B +7% $1.8B $321MM $1.3B MIMEDX 2023 Net Sales 2023 2028E U.S. Wound U.S. Surgical Japan Introduction of Xenografts for Surgical Applications Meaningfully Grows
Slide 9: Large Placental Donation Network & Proprietary Tissue Processing Technology
Large Placental Donation Network & Proprietary Tissue Processing Technology Placental Donation Network Proprietary Processing 5 1 2 3 4 6 7 Expectant Mom Mom Consents to Delivery of Healthy Donated Placental Microbiological Proprietary Shelf-stable Introduced to Donate and Completes Baby via Tissues
Slide 10: Diversified Business Across Multiple Sites of Service
Diversified Business Across Multiple Sites of Service Site of Segment Commentary Service Hospital Setting Stable reimbursement (Inpatient & settings and growing with Outpatient) & expanded use of products in Wound Care surgical applications Clinics Medicare reimbursement evolving, resulting in Priva
Slide 11: Physician Office Medicare Reimbursement Overhaul Underway
Physician Office Medicare Reimbursement Overhaul Underway Led to an increase in skin substitutes With a significant number of these Scrutiny of excessive Medicare Allowed Resulting in a de-facto 3 1 2 on the Medicare ASP List Charges for skin substitutes under WAC products priced above $500/sq. cm n
Slide 12: Our Strategic Priorities
Our Strategic Priorities • Continue momentum with new organic products in Wound & Surgical Innovate & Diversify Build leadership position Product Portfolio to • Consider additional inorganic additions in Wound & Surgical Maximize Growth to our product offering • Drive further uptake of EPIFIX in Jap
Slide 13: Q1:24 Highlights
Q1:24 Highlights 1 Net Income Net Sales Gross Margin Adjusted EBITDA $9MM $85MM 85% $19MM +18% year-over-year 22% of net sales Portfolio Expansion Free Cash Flow Cash Balance Launched into Xenografts $5MM $48MM E-Commerce & Account Management Platform 1 – EBITDA, Adjusted EBITDA, related margins and
Slide 14: Management Team with Track Record of Success in MedTech
Management Team with Track Record of Success in MedTech Doug Rice Joe Capper Ricci Whitlow John Harper, Ph.D. Kim Moller Eric Smith Butch Hulse Kate Surdez Matt Notarianni Chief Financial Chief Executive Chief Operating Chief Scientific Officer & SVP, Sales SVP, Marketing & Chief Administrative Chie
Slide 15: Conclusion
Conclusion Pioneer and Expanding Large and Committed to leader in pipeline in growing delivering above- Advanced Wound Wound & market market growth Care Surgical opportunities and profitability helping humans heal. 15